Louisville, KY (PRWEB) November 07, 2013
Neuronetrix has been selected to present at the 6th Annual Conference on Clinical Trials for Alzheimer’s Disease (CTAD) in San Diego, CA on Nov 15, 2013. CTAD is the foremost conference where leading pharmaceutical companies discuss their strategic plans for drug development efforts to treat Alzheimer’s disease.
Neuronetrix will present novel methods for analyzing complex electrophysiological measures of cognitive function. The data was collected as part of a large, multi-center clinical trial with over 200 subjects using the company’s COGNISION™ System.
“Pharmaceutical companies demand sensitive, reliable, reproducible measures of the cognitive effects of treatment… COGNISION™ provides these measures,” said KC Fadem, CEO of Neuronetrix. “This conference will give Neuronetrix the opportunity to showcase our game-changing technology.”
The COGNISION™ System is a proprietary, neurodiagnostic device which enables objective assessments of cognitive function using a non-invasive technology called event-related potentials (ERP).
Neuronetrix is a leading neurodiagnostic company focused on revolutionizing the diagnosis of patients with neurologic disorders by providing accurate and meaningful diagnostic information to physicians and pharmaceutical companies early in the disease process.
Information about Neuronetrix is available at http://www.neuronetrix.com or by contacting Daniel Lawson at dlawson(at)neuronetrix(dot)com, or (502) 561-9040, x7003.